Vivek Ra­maswamy bags op­tion rights on Dai­ichi’s pipeline drugs; Achillion drops a lead pro­gram; Zio­pharm cre­ates new de­vel­op­ment com­pa­ny for Chi­na

→ No longer con­tent to pick off 1 drug at a time for his grow­ing sta­ble of com­pa­nies, Roivant chief Vivek Ra­maswamy has struck a deal that gives him op­tions on a slate of pro­grams in de­vel­op­ment at Dai­ichi Sankyo. And he can use these new drugs to seed the pipelines of his fu­ture star­tups.

→ At a time high in­sulin prices have be­come a light­ning rod is­sue in the US, No­var­tis is team­ing up with Chi­na’s Gan & Lee to pro­vide cheap­er knock­offs of three big brands.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.